News

Copycats attack Abbott's Humira
Enlarge image

BusinessSwitzerlandGermanyMalta

Copycats attack Abbott's Humira

31.10.2012 - With AET Biotech Ltd. and BioXpress SA, two new players join the queue of Humira copycats.

The two partners pool their expertise in the manufacturing of biologicals and in development and marketing. The TNF-alpha blocker is a promising target with projected global sales of more US$9bn this year. Malta-based AET BioTech Ltd. is the biosimilars operation of German generic drugs firm Alfred E. Tiefenbacher GmbH & Co. KG in Hamburg. BioXpress S.A. is a Swiss biotech focused on the development of monoclonal antibody biosimilars.

The firms aim to jointly develop the biosimilar to registration, based on BioXpress expression technology. AET will shoulder commercialisation of the resulting antibody and will, in addition, provide further investment in terms of committed long-term financing.
The Humira patent runs out in 2016. However, Abbott is trying to prevent biosimilar competition by legal action. Furthermore, larger players like Boehringer Ingelheim are already developing Humira follow-on biologics. Humira has an interesting history. Originally the drug was developed by German BASF AG who sold its pharma business to Abbott.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/copycats-attack-abbotts-blockbuster.html

2014EU

19.12.2014 We took a look back at 2014: which European Biotechnology News stories topped the charts this year?

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

Events

All Events

Current issue

All issues

Product of the week

Products